Abstract
Background
Patients admitted to hospital with acute severe ulcerative colitis have a short-term in-hospital colectomy rate of 30%. The Oxford criteria state that if the CRP is greater than 45 mg/l or there are more than eight bowel movements in 24 h at day 3 of intravenous corticosteroids, there is an 85% risk of an in-hospital colectomy.
Aim
The aim of this study was to determine whether this high rate of colectomy continues to be accurate in this medically refractory patient population.
Methods
We performed a retrospective chart review of 80 patients admitted to a tertiary hospital between 2013 and 2017 with acute severe ulcerative colitis.
Results
Sixteen (20%) patients required an in-hospital colectomy. Of the 33 patients that fulfilled the Oxford criteria, 12 (36%) patients required a colectomy during admission. Only four (9.5%) patients who did not fulfill the Oxford criteria required a colectomy during admission. Twenty-two patients that had fulfilled the Oxford criteria received infliximab as second-line medical therapy.
Conclusion
In a patient population that fulfilled the Oxford criteria, the in-hospital colectomy rate has reduced from 85% in 1996 to 36% in 2017. These results should be considered when discussing with patients the opportunity to commence infliximab or cyclosporine as second-line medical therapy.
Similar content being viewed by others
References
Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299–315.
Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179–194.
Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4:431–437.
Ananthakrishnan AN, McGinley EL, Binion DG, et al. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–276.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. BMJ. 1954;2:375–378.
Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.
Parragi L, Fournier N, Zeitz J, et al. Colectomy rates in ulcerative colitis are low and decreasing: 10-year follow-up data from the Swiss IBD Cohort study. J Crohns Colitis. 2018;12:811–818.
Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–515.
Gallagher ND, Goulston SJM, Wyndham N, et al. The management of fulminant ulcerative colitis. Gut. 1962;3:306–311.
Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–910.
Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6:1112–1116.
Kassim O, Micic D, Christensen B, et al. P454 Can calcineurin inhibitors induce a durable remission that is maintained with vedolizumab in IBD? J Crohns Colitis. 2017;11:S309.
Halmos EP, Biesiekierski JR, Newnham ED, et al. Inaccuracy of patient-reported descriptions of and satisfaction with bowel actions in irritable bowel syndrome. Neurogastroenterol Motil. 2018. https://doi.org/10.1111/nmo.13187.
Author information
Authors and Affiliations
Contributions
AM was involved in analysis and interpretation of data and drafting of the manuscript. BB was involved in the critical revision of the manuscript for important intellectual content.
Corresponding author
Ethics declarations
Conflict of interest
Brian Bressler is an advisor and speaker for Shire, Ferring, Janssen, Abbvie, Takeda and Actavis and an advisor for Amgen, Pendopharm, Genentech, Celltrion, Pfizer, Allergan and Protagonist. Research support is provided by Janssen, Abbvie, GSK, BMS, Amgen, Genentech, Merck, RedHill Biopharm, BI, Qu Biologic, Celgene, and Alvine. He has stock options with Qu Biologic. There are no financial disclosures or other relevant conflicts of interest for any other author.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Moore, A.C., Bressler, B. Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates. Dig Dis Sci 65, 576–580 (2020). https://doi.org/10.1007/s10620-019-05668-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-019-05668-6